RxDoctor Payments Data

Jeffrey Elliott, MD

Internal Medicine · Dothan, ALNPI 1639138795

Payments from drug & device makers

$1,992in general payments, 2019–2025

Across 138 payments — averaging $14.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$347
  • Astellas Pharma US Inc$340
  • AbbVie$317
  • Novo Nordisk$265
  • Nevro Corp.$197
  • GSK$140
  • plus $385 from 10 others

What the payments were for

  • Food & beverage$1,992100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,992 in reported general payments places this provider in the 70th percentile of 1,533 internal medicine providers in Alabama.

See all internal medicine providers in Alabama

Medicare billing

Part B allowed, 2024
$551,365
Medicare patients
1,056
Services billed
12,466

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin177$198,360
MounjaroTirzepatide146$195,771
EliquisApixaban174$144,052
OzempicSemaglutide90$109,709
TrulicityDulaglutide49$66,837
JanuviaSitagliptin Phosphate42$45,233
XareltoRivaroxaban36$37,967
FarxigaDapagliflozin Propanediol45$36,167
Trelegy ElliptaFluticasone/Umeclidin/Vilanter44$35,955
Breo ElliptaFluticasone/Vilanterol40$29,329
TradjentaLinagliptin31$26,781
MyrbetriqMirabegron37$24,872
Tresiba Flextouch U-100Insulin Degludec31$24,670
LinzessLinaclotide20$22,863
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog24$20,270

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity, Humulin 70-30$15$267,606215 claims
PfizerEliquis$37$144,052174 claims
Novo NordiskOzempic$265$109,70990 claims
GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta$140$69,91196 claims
Johnson & JohnsonXarelto$347$37,96736 claims
AbbVieLinzess, Restasis$317$27,13732 claims
Astellas Pharma US IncMyrbetriq$340$24,87237 claims
NovartisEntresto$14$14,49717 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,533 internal medicine providers in Alabama.

Other internal medicine in Dothan

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →